Source comparison
Selective versus Non-Selective: the Afamelanotide and Bremelanotide Comparison
The clearest way to understand Melanotan II’s place in pigmentation research is to see it against the two approved melanocortin drugs that flank it. The comparison is not academic; it explains why one molecule became a medicine for pigmentation and another did
This comparison does not assign a generated winner or score.
- The clearest way to understand Melanotan II’s place in pigmentation research is to see it against the two approved melanocortin drugs that flank it. The comparison is not academic; it explains why one molecule became a medicine for pigmentation and another did not.
- Afamelanotide (Scenesse) is the pigmentation success story of this family. As a functionally MC1R-directed agonist delivered by a bioresorbable subcutaneous implant under specialist supervision, it increases epidermal eumelanin independent of UV and thereby extends the time patients with erythropoietic protoporphyria can spend in light without triggering the excruciating phototoxic reactions that define their disease.8 It earned European approval in 2014 and FDA approval in October 2019 for that narrow indication, on the strength of randomized controlled trials.8 Notably, afamelanotide is not approved or marketed as a cosmetic tanning agent; even the approved MC1R drug is deployed only for a specific medical need, with the pigmentation effect harnessed as photoprotection rather than aesthetics.
- Bremelanotide (Vyleesi) is the other approved relative, and it demonstrates the family’s logic from the opposite direction. Rather than steering toward MC1R and pigmentation, its development steered toward the MC4R sexual-desire axis, and it was approved by the FDA in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women, administered by subcutaneous autoinjector before anticipated activity.3 Its documented efficacy is modest — in the pivotal trials roughly a quarter of treated patients met the desire-score threshold versus about a sixth on placebo — and it carries its own melanocortin-class effects including nausea and transient blood-pressure elevation.3 Both approved drugs, in short, are the products of deliberate receptor targeting.
- Melanotan II is the untargeted middle. It hits everything the two approved drugs each hit selectively, which is why it produces both tanning and the sexual/autonomic effects at once, and why it never became a controlled medicine for either. Placing it beside its approved cousins is the most honest single frame for the compound: not a novel or promising therapeutic, but the non-selective ancestor from which selective, approved agents were carved. Researchers cataloging how these compounds are distinguished can find the broader melanocortin landscape organized in the site’s peptide research catalog.